William Blair Increases Earnings Estimates for Genmab A/S
William Blair upped their FY2028 EPS estimates for Genmab A/S in a research note issued on Monday, March 10th. William Blair ...
Morgan Stanley Remains a Hold on Genmab (GMAB)
Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Genmab (GMAB – Research Report) today and set a price target of $25.00. The ...
Genmab A/S (NASDAQ:GMAB) Shares Sold by Assetmark Inc.
Assetmark Inc. lowered its position in Genmab A/S (NASDAQ:GMAB – Free Report) by 78.1% during the fourth quarter, Holdings ...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in ...
BioPharma Dive1d
A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV
Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is ...
Genmab A/S (0MGB) Gets a Buy from Barclays
Barclays analyst Emily Field maintained a Buy rating on Genmab A/S (0MGB – Research Report) today and set a price target of DKK2,100.00. The ...
Fintel on MSN2d
William Blair Upgrades Genmab A (GMAB)
Fintel reports that on March 11, 2025, William Blair upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market Perform ...
Market Inference2d
Key Focus for Genmab A/S Investors
Genmab A/S has a trailing 12 month Price to Earnings (P/E) ratio of 11.6 while the S&P 500 average is 29.3 Its forward ...
Nordic Shares Decline; Genmab Falls Furthest
Stocks in the Nordic region declined Tuesday, with the OMX Nordic 40 Index declining 2.2%. Genmab A/S posted the largest decline among large stocks during the session, declining 9.2%, followed by ...
Genmab says J&J not exercising option on HexaBody-CD38
Genmab (GMAB) announced that Johnson & Johnson (JNJ) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38. “While the ...
The Pharma Letter3d
J&J pulls out of HexaBody-CD38 collaboration with Genmab
Danish cancer specialist Genmab’s stock took a hit after US healthcare giant Johnson & Johnson opted not to license its ...
pharmaphorum3d
J&J abandons work with Genmab on Darzalex successor
A head-to-head trial of HexaBody-CD38 versus Darzalex Faspro revealed an overall response rate (ORR) of 55% and 52%, respectively, with Genmab pointing to "deeper responses" with the new drug and a ...